Shrunken pore syndrome: Difference between revisions
Anders Grubb (talk | contribs) Added two links |
Anders Grubb (talk | contribs) m Added two links |
||
Line 2: | Line 2: | ||
[[File:Inner view of fenestrae in capillary of glomerulus in Scanning Electron Microscope, magnification 100,000x.GIF|thumb|Pores in one of the structures of the glomerular filtration barrier]] |
[[File:Inner view of fenestrae in capillary of glomerulus in Scanning Electron Microscope, magnification 100,000x.GIF|thumb|Pores in one of the structures of the glomerular filtration barrier]] |
||
'''Shrunken pore syndrome''' (SPS) is a [[kidney disorder]] described in 2015 in which the pores in the [[Glomerulus_(kidney)#Filtration|glomerular filtration barrier]] are hypothesized to have shrunken so that the filtration of 5–30 [[kDa]] proteins, for example [[cystatin C]], is reduced.<ref name= Grubb2020/> The [[syndrome]] is associated with premature death.<ref name= Grubb2020/><ref name= Zhou2019/> SPS has been identified in children.<ref name= Grubb2020/> |
'''Shrunken pore syndrome''' (SPS) is a [[kidney disorder]] described in 2015 in which the pores in the [[Glomerulus_(kidney)#Filtration|glomerular filtration barrier]] are hypothesized to have shrunken so that the filtration of 5–30 [[kDa]] [[proteins]], for example [[cystatin C]], is reduced.<ref name= Grubb2020/> The [[syndrome]] is associated with premature death.<ref name= Grubb2020/><ref name= Zhou2019/> SPS has been identified in children.<ref name= Grubb2020/> |
||
==Mechanism== |
==Mechanism== |
||
[[File:Bowman's capsule and glomerulus.svg|thumb|Glomerulus and Bowman's capsule. The blood filtered through the glomerular filtration barrier corresponds to the primary urine collected in the Bowman's capsule.]] |
[[File:Bowman's capsule and glomerulus.svg|thumb|Glomerulus and Bowman's capsule. The blood filtered through the glomerular filtration barrier corresponds to the primary urine collected in the Bowman's capsule.]] |
||
It has been speculated that SPS is both caused by, and exacerbates, [[cardiovascular disease]].<ref name= Grubb2020/> It was stated in 2014 that the kidneys have a role in maintaining the equilibrium between production and catabolism of most proteins between about 5 and 30 kDa in [[molecular mass]] and that failure to do so results in serious disease and strongly increased mortality, when the kidney disorder shrunken pore syndrome was identified.<ref name=Zhou2019>{{cite journal | vauthors = Zhou H, Yang M, He X, Xu N | title = eGFR, cystatin C and creatinine in shrunken pore syndrome | journal = Clinica Chimica Acta | volume = 498 | pages = 1–5 | date =Nov 2019 | pmid = 31398310 | doi = 10.1016/j.cca.2019.08.001 |type= Review}}</ref> Proteins less than 30 kDa comprise about 36% of the total human [[proteome]].<ref name=Grubb2020/> A [[hypothesis]] concerning the [[pathophysiology]] of SPS is that several 5–30 kDa proteins with signalling functions, e.g. [[cytokines]], are increased in concentration and promote development of serious disorders like cancer and cardiovascular disorders.<ref name=Grubb2020/> |
It has been speculated that SPS is both caused by, and exacerbates, [[cardiovascular disease]].<ref name= Grubb2020/> It was stated in 2014 that the kidneys have a role in maintaining the equilibrium between production and [[catabolism]] of most proteins between about 5 and 30 kDa in [[molecular mass]] and that failure to do so results in serious disease and strongly increased mortality, when the kidney disorder shrunken pore syndrome was identified.<ref name= Grubb2020/><ref name=Zhou2019>{{cite journal | vauthors = Zhou H, Yang M, He X, Xu N | title = eGFR, cystatin C and creatinine in shrunken pore syndrome | journal = Clinica Chimica Acta | volume = 498 | pages = 1–5 | date =Nov 2019 | pmid = 31398310 | doi = 10.1016/j.cca.2019.08.001 |type= Review}}</ref> Proteins less than 30 kDa comprise about 36% of the total human [[proteome]].<ref name=Grubb2020/> A [[hypothesis]] concerning the [[pathophysiology]] of SPS is that several 5–30 kDa proteins with signalling functions, e.g. [[cytokines]], are increased in concentration and promote development of serious disorders like cancer and cardiovascular disorders.<ref name=Grubb2020/> |
||
==Diagnosis== |
==Diagnosis== |
Revision as of 12:41, 22 August 2020
This article needs more links to other articles to help integrate it into the encyclopedia. (August 2020) |
Shrunken pore syndrome (SPS) is a kidney disorder described in 2015 in which the pores in the glomerular filtration barrier are hypothesized to have shrunken so that the filtration of 5–30 kDa proteins, for example cystatin C, is reduced.[1] The syndrome is associated with premature death.[1][2] SPS has been identified in children.[1]
Mechanism
It has been speculated that SPS is both caused by, and exacerbates, cardiovascular disease.[1] It was stated in 2014 that the kidneys have a role in maintaining the equilibrium between production and catabolism of most proteins between about 5 and 30 kDa in molecular mass and that failure to do so results in serious disease and strongly increased mortality, when the kidney disorder shrunken pore syndrome was identified.[1][2] Proteins less than 30 kDa comprise about 36% of the total human proteome.[1] A hypothesis concerning the pathophysiology of SPS is that several 5–30 kDa proteins with signalling functions, e.g. cytokines, are increased in concentration and promote development of serious disorders like cancer and cardiovascular disorders.[1]
Diagnosis
An eGFRcystatin C/eGFRcreatinine-ratio <0.60, or <0.70, in the absence of non-renal influences on eGFRcystatin C or eGFRcreatinine, identifies a condition as SPS.[1] Optimal classification and stratification of chronic kidney disease requires not only analysis of GFR (estimated or measured) and albuminuria, but also determination of the eGFRcystatin C/eGFRcreatinine-ratio to assess the presence of SPS.[1]
Prognosis
The mortality of SPS was higher than that of cancer, diabetes mellitus, cardiovascular disease or chronic kidney disease.[1]
References
- ^ a b c d e f g h i j Grubb A (Sep 2020). "Shrunken pore syndrome – a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options". Clinical Biochemistry (Review). 83: 12–20. doi:10.1016/j.clinbiochem.2020.06.002. PMID 32544475.
- ^ a b Zhou H, Yang M, He X, Xu N (Nov 2019). "eGFR, cystatin C and creatinine in shrunken pore syndrome". Clinica Chimica Acta (Review). 498: 1–5. doi:10.1016/j.cca.2019.08.001. PMID 31398310.